The global oncology based molecular diagnostics market size is likely to be valued at US$5.6 billion in 2026 and is estimated to reach US$8.5 billion by 2033, growing at a CAGR of 6.3% during the forecast period from 2026 to 2033, driven by the rising adoption of precision oncology and increasing use of next-generation sequencing for cancer profiling. Expanding biomarker testing in routine clinical practice is also predicted to support market growth.

Driver - Rising Adoption of Liquid-Biopsy Companion Diagnostics

Circulating tumor Deoxyribonucleic Acid (ctDNA)-based liquid biopsy tests are moving from optional add-on to a mandatory step in treatment selection. When a test is designated a companion diagnostic (CDx), clinicians must use it to confirm eligibility before prescribing a specific drug. In November 2024, the Food and Drug Administration (FDA) approved FoundationOne Liquid CDx as a companion diagnostic for tepotinib in adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) harboring MET exon 14 skipping alterations.

The same platform has received CDx approval for drugs targeting BRAF V600E mutations and NTRK1-3 fusions in solid tumors. In June 2026, Quest Diagnostics announced that its Haystack MRD liquid biopsy test, which received Breakthrough Device Designation from the FDA in 2025 for use in Stage II colorectal cancer, received New York State Department of Health approval. This authorized the test for patient use in all 50 U.S. states. Each new CDx designation adds a mandated testing requirement to the clinical pathway, thereby expanding the addressable patient volume for liquid biopsy platforms.

Increasing Genomics Reimbursement Initiatives

National-level investment in genomic medicine creates a funded testing infrastructure that increases the volume of molecular diagnostics ordered, regardless of individual patient affordability. According to a peer-reviewed article published in The Lancet Regional Health – Europe (January 2025) describing the French Plan France Médecine Génomique 2025 (PFMG2025), since 2016 the French government has invested €239 million (approx. US$272.1 million) in the initiative. It has focused on patients with rare diseases, cancer genetic predisposition, and oncology.

This helped in establishing a nationwide clinical pathway from tumor board prescription through sequencing to results delivery. Belgium took a complementary step on July 1, 2024, when Belgium's National Institute for Health and Disability Insurance (INAMI/RIZIV) introduced permanent reimbursement for Next-Generation Sequencing (NGS) in oncology and hemato-oncology through 51 newly introduced pseudo-nomenclature billing codes. It converted what had been a five-year pilot program into a standard-of-care reimbursement pathway. As more governments formalize genomics reimbursement, the conversion rate of eligible patients into actual molecular diagnostic tests rises.

Restraint - Reimbursement Gaps May Hamper Adoption

The unit cost of oncology molecular diagnostics remains a significant barrier to routine clinical use, especially in low-income countries and in healthcare networks where insurance coverage for genomic testing remains inconsistent. According to a 2025 GlobeNewswire industry analysis citing testing cost data, a single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems, with insufficient diagnostic infrastructure, mainly in rural areas, exacerbating access disparities further.

A systematic review published in Value in Health (May 2024) confirmed the underlying economic tension. A key hurdle in broad NGS biomarker testing access in oncology is the ongoing debate on NGS's cost-effectiveness, with current biomarker testing relying on single-gene biomarker assays that are inexpensive but only detect a single mutation. Questions on NGS cost-effectiveness hinder wide adoption despite its clinical advantages. A separate real-world analysis published in the Journal of Clinical Oncology confirmed that NGS test pricing varied from US$1,722 to US$2,249 per test for hereditary cancer panels. Coverage and reimbursement was identified as one of the key policy challenges that must be addressed to reduce barriers to access.

Opportunity - High Popularity of Decentralized Molecular Testing

The shift toward Point-of-Care (POC) molecular testing provides a practical pathway for delivering cancer diagnostics in community clinics, rural health centers, and low-resource settings, without requiring shipment to a central laboratory. A comprehensive review published in JCO Global Oncology (May 2025) confirmed that POC technologies deliver a transformative approach to decentralizing cancer diagnostics by providing rapid, affordable, and expandable testing in resource-constrained settings. Recent advances, including Loop-Mediated Isothermal Amplification (LAMP) and multiplexed lateral flow immunoassay, are enabling high-sensitivity detection of cancer biomarkers without complex laboratory infrastructure.

The National Institutes of Health (NIH) is funding this transition. In October 2023, the NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) granted US$7.8 million over five years to the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT). It was granted to fuel the development and clinical translation of microsystems-based POC diagnostic platforms for cancer and other conditions. As portable molecular platforms develop, oncology diagnostics are expected to become accessible in the same visit-and-treat model that has proven effective for infectious disease POC testing.

Emergence of AI-Assisted Synthetic-Control Trials

Validating a new oncology molecular diagnostic traditionally requires a prospective clinical study with a concurrent control group. The process takes years and demands large patient cohorts. AI-assisted Synthetic Control Arms (SCAs) are compressing this timeline by replacing or augmenting concurrent control groups with historical patient data matched to the study protocol. Medidata AI's SCA platform, used in regulatory submissions to the FDA and European Medicines Agency (EMA), is designed to support regulatory interactions. It includes enhancing single-arm Phase II trials, supporting accelerated approval submissions, and aiding confirmatory Phase III trials.

The platform is helping to reduce enrollment requirements; for example, helping Medicenna reduce its Phase III registration trial enrollment by two-thirds. The FDA has formally acknowledged the surging role of AI in regulatory science. According to a Journal of Chemistry (Wiley, February 2026) review of the FDA's January 2025 draft guidance, as of December 2024, the FDA had authorized over 1,000 AI-based medical devices. In January 2025, it issued its inaugural draft guidance specifically addressing the application of AI in regulatory decision-making for pharmaceuticals and biological products. For molecular diagnostic companies, this guidance creates a transparent approval pathway when AI-generated evidence supports assay validation.

Product Type Insights

Reagents are predicted to lead with a share of approximately 59.2% in 2026, as they are consumed every time a molecular test is performed. Unlike instruments, which are purchased once and used for several years, reagents such as PCR master mixes, sequencing library preparation kits, extraction kits, probes, primers, and quality control materials must be replenished regularly. As cancer testing volumes increase, laboratories generate recurring demand for these consumables, making reagents the primary revenue source for diagnostic companies.

Instruments are estimated to be the fastest-growing segment over the forecast period, as healthcare providers are replacing conventional PCR systems with automated next-generation sequencing (NGS), digital PCR, and integrated molecular diagnostic platforms. Hospitals and reference laboratories prefer instruments that can process large sample volumes with minimal manual intervention while delivering fast turnaround times. Another key driver is the rising adoption of decentralized molecular testing. Diagnostic companies are introducing compact systems that can perform sample preparation, sequencing, and data analysis in a single workflow.

Cancer Type Insights

The breast cancer segment is anticipated to dominate with a share of nearly 20.4% in 2026, as it has one of the most established precision medicine networks among all cancers. Clinical management routinely depends on molecular biomarkers such as HER2, BRCA1/2, PIK3CA, ESR1, and NTRK, making molecular diagnostics an essential part of treatment selection rather than an optional test. The high number of targeted therapies has significantly increased demand for companion diagnostics. Each newly approved therapy requires accurate biomarker testing before treatment begins.

The prostate cancer segment is expected to remain in the second position in 2026, as clinical practice is moving beyond PSA testing toward molecular and genomic profiling. Physicians now use genomic biomarkers to distinguish aggressive disease from slow-growing tumors, helping avoid unnecessary treatment while identifying patients who require early intervention. Genomic risk assessment is also becoming standard for treatment planning. In April 2025, Veracyte expanded its Decipher Prostate genomic classifier to include patients with metastatic prostate cancer.

North America Oncology Based Molecular Diagnostics Market Trends

North America is predicted to dominate in 2026 with a global share of approximately 46.3%, as it has the most well-established precision oncology hub. The region has a high concentration of global diagnostics companies, academic cancer centers, reference laboratories, and pharmaceutical firms that develop companion diagnostics alongside targeted cancer drugs. This creates faster adoption of new molecular tests than in most other regions. The region also benefits from well-established reimbursement pathways for comprehensive genomic profiling and liquid biopsy, encouraging routine clinical use.

U.S. Oncology Based Molecular Diagnostics Market Trends

A share of nearly 67.7% is expected to be held by the U.S. in 2026 in North America, as precision medicine has become part of routine cancer care. Hospitals today perform next-generation sequencing (NGS), liquid biopsy, and comprehensive genomic profiling before selecting targeted therapies. As more oncology drugs require biomarker testing, molecular diagnostics has become an essential clinical step instead of an optional investigation. The country is also the global hub for oncology innovation. Companies such as Guardant Health, Tempus, Illumina, Thermo Fisher Scientific, and Foundation Medicine continue to introduce new molecular assays and AI-enabled genomic platforms.

Asia Pacific Oncology Based Molecular Diagnostics Market Trends

Asia Pacific is anticipated to be the fastest-growing region worldwide in 2026 with a share of nearly 29.8%, as governments are investing heavily in cancer diagnosis, genomic medicine, and precision healthcare. Countries across the region are extending molecular testing capacity by establishing genomic laboratories, strengthening cancer screening programs, and increasing access to targeted therapies. These efforts are making advanced molecular diagnostics available beyond key metropolitan hospitals.

China Oncology Based Molecular Diagnostics Market Trends

China will likely lead in Asia Pacific in 2026 with a regional share of around 39.6%, as it has rapidly expanded its genomic research and precision oncology capabilities. The country has increased investments in sequencing infrastructure, cancer genomics, and biotechnology innovation. Local hospitals are adopting NGS panels and liquid biopsy for tumor profiling, especially in large tertiary care centers. China has also become a global leader in oncology research. According to the IQVIA Institute, China-based pharmaceutical companies initiated 35% of all new oncology clinical trials in 2023, surpassing U.S.-based companies for the first time.

India Oncology Based Molecular Diagnostics Market Trends

In 2026, India is projected to account for a regional share of approximately 28.3% in Asia Pacific, as advanced molecular testing is becoming more accessible in both public and private healthcare. Leading hospitals and diagnostic chains are offering NGS panels, hereditary cancer testing, and liquid biopsy services. This has improved access to precision oncology beyond a few research institutions. Government initiatives are further supporting this transition. Programs promoting genomic research and digital health infrastructure are encouraging the adoption of molecular diagnostics.

Europe Oncology Based Molecular Diagnostics Market Trends

Europe will likely witness steady growth over the forecast period with a global share of nearly 15.2% in 2026, as molecular diagnostics is being integrated into national cancer strategies across several countries. Healthcare systems recommend biomarker testing before prescribing targeted oncology therapies. This has resulted in consistent demand for companion diagnostics, NGS, and liquid biopsy services across hospitals and reference laboratories. Another important driver is the implementation of the European Union In Vitro Diagnostic Regulation (IVDR). The regulation has encouraged manufacturers to strengthen clinical evidence and improve the quality of molecular diagnostic products.

Germany Oncology Based Molecular Diagnostics Market Trends

Germany will likely register a substantial regional share of approximately 38.8% in 2026 in Europe, owing to its advanced hospital infrastructure and widespread use of precision oncology. Comprehensive cancer centers routinely perform molecular profiling for lung, breast, colorectal, and hematological cancers. The country also hosts several leading research institutes that contribute to biomarker discovery and translational oncology research. Germany is further benefiting from increasing collaboration between academic institutions, diagnostic companies, and pharmaceutical manufacturers.

U.K. Oncology Based Molecular Diagnostics Market Trends

A regional share of around 16.7% is predicted to be held by the U.K. in 2026 in Europe, as the National Health Service (NHS) is steadily broadening genomic medicine through the NHS Genomic Medicine Service. Patients with several cancer types are being offered genomic testing to identify mutations that can guide targeted treatment. This is raising the routine use of molecular diagnostics in clinical oncology. The U.K. also benefits from a superior research environment. Organizations such as Genomics England continue to support large-scale genomic sequencing and cancer research. These initiatives generate valuable genomic datasets that improve biomarker discovery.

The global oncology based molecular diagnostics market is moderately consolidated with a handful of multinational diagnostics companies controlling core technologies such as Next-Generation Sequencing (NGS), PCR, companion diagnostics, and liquid biopsy. Companies such as Roche, Thermo Fisher Scientific, QIAGEN, Illumina, and Danaher combine sequencing instruments, assay kits, bioinformatics software, pathology solutions, and companion diagnostics to create end-to-end workflows that are difficult for small competitors to replicate.

Roche further strengthened its competitive position through Foundation Medicine, while its recent launch of the Axelios sequencing platform signals a challenge to Illumina's long-standing dominance in sequencing infrastructure. Strategic partnerships with pharmaceutical companies have become one of the most prominent competitive differentiators. Diagnostic developers co-develop companion diagnostics alongside targeted oncology drugs, allowing them to secure long-term testing demand after drug approvals.

Key Industry Developments:

• In May 2026, Roche announced a definitive merger agreement to acquire PathAI for US$750 million upfront and up to US$300 million in milestone payments. The companies stated that integrating PathAI's AI-assisted digital pathology platform with Roche's companion diagnostics portfolio would boost biomarker discovery, strengthen AI-enabled cancer diagnostics, and support the development of new precision oncology tools.
• In April 2026, Foundation Medicine revealed plans to integrate SAGA Diagnostics' Pathlight platform with Roche's AXELIOS sequencing system and Digital LightCycler PCR platform. The initiative aims to develop a decentralized MRD testing solution that can expand access to highly sensitive molecular cancer monitoring across healthcare settings worldwide.
• In April 2026, Roche announced an agreement to acquire SAGA Diagnostics for up to US$595 million through its Foundation Medicine subsidiary. The acquisition expands Foundation Medicine's Molecular Residual Disease (MRD) portfolio with the Pathlight tumor-informed platform. It combines whole-genome sequencing and digital PCR for ultra-sensitive detection of residual cancer and recurrence monitoring.